Autoimmune disease is a medical condition that causes abnormalities in the immune response and triggers damage to the healthy body tissues. The increasing prevalence of autoimmune diseases all over the world is generating high demand for effective treatments in the global market. As per the report published by Market Research Future (MRFR), the global autoimmune disease treatment market is anticipated to expand remarkably at a noteworthy CAGR of 11.2% during the forecast period.
Key Players:
The key players of the global autoimmune disease treatment market that rea profiled in the report published by MRFR are Abbott Laboratories, Amgen Inc., Genentech Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bio-Rad, Chugai Pharmaceutical Co. Ltd., Danaher, Elan Corporation Plc, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, HYCOR Biomedical, Johnson & Johnson Inc., Merck & Co. Inc., Siemens, Squibb Company, Thermo Fisher Scientific, and others.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5586
Market Drivers:
The rise in number of individuals suffering from IBD, rheumatoid arthritis, psoriasis, sclerosis and other autoimmune diseases is causing the rise in demand for treatments in the global market, resulting in the expansion of the global autoimmune disorder treatment market. The increasing prevalence of common autoimmune disease such as diabetes is one of the major factors driving the growth of the global autoimmune disease treatment market.
The pharmaceutical companies are focusing on introducing highly effective medication and treatments to control and treat the symptoms of autoimmune diseases by increasing the research and development expenditure, which in turn is fueling the expansion of the global autoimmune disease treatment market. The increasing prevalence of other autoimmune diseases such as Addison’s disease, celiac disease, thyroid disorder and others and the rise in number of geriatric population affected by autoimmune diseases is causing the rise in demand for high-quality treatments in the global market, which is positively impacting the growth of the global autoimmune disease treatment market.
Market Restraints:
The lack of information regarding the cause of autoimmune disease, low penetration of advanced treatments in the underdeveloped regions due to the absence of necessary healthcare infrastructure and lack of awareness regarding the availability of treatments of autoimmune diseases are likely to act as a restraint on the expansion of the global autoimmune disease treatment market during the forecast period.
Market Segmentation:
The global autoimmune disease treatment market has been segmented on the basis of disease type, diagnosis, therapeutic products and distribution channel.
Based on disease types, the autoimmune disease treatment market is segmented into localized and systematic. The localized segment is sub-segmented into multiple sclerosis, inflammatory bowel disease, diabetes, and others. The systematic disease type segment is sub-segmented into rheumatoid arthritis, psoriasis, lupus, and others.
Based on diagnosis, the autoimmune disease treatment market is segmented into ELISA, dot blot, line blot, agglutination, double immune diffusion, western blotting, multiplex immunoassay, and others.
Based on therapeutic products, the autoimmune disease treatment market is segmented into drugs, and therapeutic and monitoring equipment. The drugs segment includes biologics, immunosuppressant, anti-inflammatory drugs, corticosteroids, and non-steroidal anti-inflammatory drugs.
Based on distribution channel, the autoimmune disease treatment market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.
Regional Analysis:
Geographically, the global autoimmune disease treatment market is segmented into four major regions such as Americas, Europe, Asia Pacific and the Middle East and Africa. The Americas is projecting dominance on the global autoimmune disease treatment market owing to the high prevalence of autoimmune diseases and well-developed healthcare infrastructure in this region.
The Europe region is projected to account for the second largest share in the global autoimmune disease treatment market owing to the increasing investment in the healthcare sector and rise in healthcare expenditure by the population in this region.
The Asia Pacific region is projecting fastest growth in the global autoimmune disease treatment market owing to the high population and increasing pool of individuals suffering from autoimmune diseases in this region.
The Middle East and Africa region is projecting slow growth in the global autoimmune disease treatment market owing to the poor healthcare infrastructure and lack of awareness in the underdeveloped areas of this region.
Competitive Landscape:
The pharmaceutical companies are focusing on increasing their research and development expenditure in order to introduce highly effective and innovative medications in the market which in turn is fueling the competition in the global autoimmune disease treatment market. The strategic mergers and acquisitions among the players are aiding the expansion of their businesses in the global autoimmune disease treatment market.
On 25th July 2018, Corbus Pharmaceuticals, a clinical stage drug development company, has announced the commencement of the phase 3 study of Lenabasum for the treatment of dermatomyositis, a rare autoimmune disease.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/autoimmune-disease-treatment-market-5586
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Email: [email protected]
Market InsightMarket reports related to the healthcare industry has been presented by Market Research Future, which states that the global autoimmune disease treatment market is anticipated to surge at a CAGR of 11.2% during the forecast period of 2017-2023.
As per the reports, there are approximately 80 different types of autoimmune disorders, but among those, multiple sclerosis, IBD, diabetes, rheumatoid arthritis, psoriasis, and more are the standard versions.
Though growing public awareness has increased the development potential of the market during the forecast period.
On the other hand, technological advancements, unmet medical needs, increasing government assistance, rising prevalence of co-existing disorders, improving regulatory framework are the prime factors contributing remarkably to the global autoimmune disease treatment market during the approaching year.
More factors such as enhancing funding and reimbursement policies as well as swelling adoption rate are uninterruptedly contributing towards the growth of the global autoimmune disease treatment market.
On the flip side, the prevalence of some issues associated with autoimmune disease treatment markets such as high cost of treatment, presence of misbranded drugs, side-effects of treatment, and weak healthcare system in low or middle-income countries can pose as a hamper the growth of the global autoimmune disease treatment market.Industry SegmentsThe global autoimmune disease treatment market in the MRFR reports have been categorized under segments such as disease type, diagnosis, therapeutic products, and distribution channels.By disease type: localized and systemic are the segments, where the localized segment additionally includes multiple sclerosis, inflammatory bowel disease, diabetes, and others.
Autoimmune Disease Treatment Market Research Information: By Disease Type (Localized, Systemic), Diagnosis (Elisa, Dot Blot, Agglutination, Others), Therapeutic Products (Drugs, Monitoring Equipment), Distribution Channel – Global Forecast Till 2027Autoimmune diseases are maladies in which the immune system of the body attacks the host.
The global autoimmune disease treatment market report by Market Research Future (MRFR) apprises readers of the pertinent drivers and challenges engulfing the market from 2017 to 2023.Market OverviewThe global autoimmune disease treatment market size is expected to balloon at 11.2% CAGR from 2017 to 2023 (forecast period).
This is supported by the survey by the National Institute of Health (NIH) which pegs the number of Americans suffering from autoimmune diseases at 23.5 million.
Technological advances, rising prevalence of comorbidities, rise of regulatory frameworks, and rise of government supported networks are other growth drivers of the market.But presence of unbranded drugs, side-effects of medications, and high treatment costs are challenges faced by the global autoimmune disease market.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5586 SegmentationThe global autoimmune disease treatment market is segmented on the basis of disease type, diagnosis, therapeutic product, and distribution channel.By disease type, the market is segmented into systemic and localized.
Systemic is further segmented into psoriasis, lupus, rheumatoid arthritis, and others.
Localized, on the other hand, is segmented into diabetes, inflammatory bowel disease, and others.By diagnosis, the autoimmune disease treatment market is segmented into multiplex immunoassay, agglutination, dot blot, line blot, ELISA, double immune diffusion, Western blotting, and others.By therapeutic product, it is segmented into drugs and therapeutic & monitoring equipment.
